Revlimid(lenalidomide)
Revlimid (lenalidomide) is a small molecule pharmaceutical. Lenalidomide was first approved as Revlimid on 2005-12-27. It is used to treat b-cell lymphoma marginal zone, follicular lymphoma, mantle-cell lymphoma, multiple myeloma, and myelodysplastic syndromes in the USA. It has been approved in Europe to treat follicular lymphoma, mantle-cell lymphoma, multiple myeloma, and myelodysplastic syndromes. It is known to target protein cereblon.
Download report
Favorite
SARS-CoV-2 Interaction
BMS
Case Study: Multiple Myeloma
Top 200 Pharmaceuticals by Retail Sales
Commercial
Trade Name
FDA
EMA
Revlimid (generic drugs available since 2021-05-21)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lenalidomide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| REVLIMID | Celgene | N-021880 RX | 2005-12-27 | 6 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lenalidomide | ANDA | 2023-05-16 |
| revlimid | New Drug Application | 2020-04-23 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
LENALIDOMIDE, REVLIMID, CELGENE | |||
| 2026-05-28 | ODE-241, ODE-245 | ||
| 2024-02-22 | ODE-131 | ||
LENALIDOMIDE, LENALIDOMIDE, DR REDDYS | |||
| 2023-03-06 | PC | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Lenalidomide, Revlimid, Celgene | |||
| 8741929 | 2028-03-08 | U-1983 | |
| 7465800 | 2027-04-27 | DS, DP | |
| 7855217 | 2024-11-24 | DS, DP | |
| 7468363 | 2023-10-07 | U-1983, U-2550, U-2551 | |
| 7968569 | 2023-10-07 | U-1984 | |
| 8492406 | 2023-10-07 | U-2550 | |
| 8530498 | 2023-05-15 | U-1984 | |
| 8648095 | 2023-05-15 | U-1984 | |
| 9101621 | 2023-05-15 | U-1985 | |
| 9101622 | 2023-05-15 | U-1986 | |
| 9155730 | 2023-05-15 | U-2550 | |
| 9393238 | 2023-05-15 | U-2550 | |
| 7189740 | 2023-04-11 | U-1982 | |
| 8404717 | 2023-04-11 | U-1982 | |
| 9056120 | 2023-04-11 | U-1982 | |
HCPCS
No data
Clinical
Clinical Trials
959 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | C90.0 | 112 | 208 | 83 | 8 | 12 | 369 | |
| T-cell lymphoma peripheral | D016411 | C84.9 | 9 | 9 | — | 1 | — | 15 | |
| T-cell lymphoma | D016399 | 3 | 3 | — | 1 | — | 6 | ||
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 2 | — | 1 | — | 3 |
| Covid-19 | D000086382 | U07.1 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 37 | 52 | 3 | — | 1 | 77 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 32 | 47 | 9 | — | 3 | 71 | |
| Myelodysplastic syndromes | D009190 | D46 | 19 | 32 | 3 | — | 3 | 52 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | 29 | 30 | 3 | — | 1 | 51 | |
| Follicular lymphoma | D008224 | C82 | 30 | 32 | 5 | — | 1 | 50 | |
| Mantle-cell lymphoma | D020522 | C83.1 | 20 | 26 | 4 | — | 3 | 42 | |
| Myeloid leukemia acute | D015470 | C92.0 | 19 | 17 | 1 | — | 1 | 34 | |
| Lymphoma | D008223 | C85.9 | 16 | 25 | 3 | — | 1 | 34 | |
| Neoplasms | D009369 | C80 | 19 | 8 | 1 | — | — | 23 | |
| Plasma cell neoplasms | D054219 | 6 | 11 | 1 | — | — | 14 |
Show 13 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | C95 | 6 | 15 | — | — | 1 | 19 | |
| Waldenstrom macroglobulinemia | D008258 | C88.0 | 13 | 12 | — | — | — | 18 | |
| Hodgkin disease | D006689 | C81 | 13 | 10 | — | — | — | 18 | |
| B-cell lymphoma marginal zone | D018442 | C88.4 | 8 | 8 | — | — | — | 13 | |
| Burkitt lymphoma | D002051 | C83.7 | 11 | 6 | — | — | — | 12 | |
| Smoldering multiple myeloma | D000075122 | 2 | 9 | — | — | — | 10 | ||
| Large-cell lymphoma anaplastic | D017728 | C84.6 | 8 | 7 | — | — | — | 10 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 7 | 4 | — | — | — | 9 | |
| Adult t-cell leukemia-lymphoma | D015459 | C91.5 | 6 | 4 | — | — | — | 9 | |
| Intraocular lymphoma | D064090 | 5 | 4 | — | — | — | 7 |
Show 85 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroblastoma | D009447 | EFO_0000621 | 3 | — | — | — | — | 3 | |
| Colonic neoplasms | D003110 | C18 | 2 | — | — | — | — | 2 | |
| Rectal neoplasms | D012004 | 2 | — | — | — | — | 2 | ||
| Disease | D004194 | EFO_0000408 | R69 | 2 | — | — | — | — | 2 |
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 | ||
| Promyelocytic leukemia acute | D015473 | C92.4 | 2 | — | — | — | — | 2 | |
| Urethral neoplasms | D014523 | EFO_0003846 | 1 | — | — | — | — | 1 | |
| Ovarian epithelial carcinoma | D000077216 | 1 | — | — | — | — | 1 | ||
| Salivary gland neoplasms | D012468 | EFO_0003826 | D11 | 1 | — | — | — | — | 1 |
| Squamous cell carcinoma of head and neck | D000077195 | 1 | — | — | — | — | 1 |
Show 26 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Residual neoplasm | D018365 | — | — | — | — | 1 | 1 | ||
| Cutaneous lupus erythematosus | D008178 | EFO_0003834 | L93.1 | — | — | — | — | 1 | 1 |
| Progression-free survival | D000077982 | — | — | — | — | 1 | 1 | ||
| Dermatomyositis | D003882 | EFO_0000398 | M33 | — | — | — | — | 1 | 1 |
| Oral ulcer | D019226 | HP_0000155 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LENALIDOMIDE |
| INN | lenalidomide |
| Description | Lenalidomide is a dicarboximide that consists of 1-oxoisoindoline bearing an amino substituent at position 4 and a 2,6-dioxopiperidin-3-yl group at position 2. It inhibits the secretion of TNF-alpha and has a role as an angiogenesis inhibitor, an antineoplastic agent and an immunomodulator. It is a member of isoindoles, a dicarboximide, a member of piperidones and an aromatic amine. Lenalidomide is a thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells. |
| Classification | Small molecule |
| Drug class | thalidomide derivatives; narcotic agonists/antagonists (normorphine type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O |
Identifiers
| PDB | — |
| CAS-ID | 191732-72-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL848 |
| ChEBI ID | 63791 |
| PubChem CID | 216326 |
| DrugBank | DB00480 |
| UNII ID | F0P408N6V4 (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
Revlimid - Bristol Myers Squibb
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Revlimid - Celgene
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,952 documents
View more details
Safety
Black-box Warning
Black-box warning for: Lenalidomide
, Revlimid
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
46,155 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more